New COPD Drugs: 2019 in Review

For primary care and other clinicians who treat COPD, 2019 was a year of innovation.FDA approved the first once-daily nebulized bronchodilator; a Breakthrough Device that delivers cryotherapy; and, the first generic of Advair Diskus. In other developments, aspirin was found to reduce COPD mortality and macrolides to reduce frequency of acute exacerbations.Scroll through the slides below for short summaries of these and other news important to optimal management of COPD.